Efficacy and Safety of Ixekizumab vs. Low-Dose IL-2 vs. Colchicine vs. Standard of Care on the Treatment of Patients Hospitalized with Moderate to Critical Covid-19: A Pilot Randomized Clinical Trial (STRUCK: Survival Trial Using Cyto kine Inhibitors)

preprint OA: closed
🔓 Open OA copy View at publisher

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00
unpaywall
last seen: 2026-06-23T06:35:03.149509+00:00